Rikin Morjaria

Profil Rikin Morjaria

Rikin advises clients on mergers and acquisitions, joint ventures, carve-outs and general corporate issues with a focus on complex cross-border deals in the Life Sciences sector.

Rikin was seconded to our Innovation practice where he helped develop some of our tech-enabled solutions and is a Legal Innovation Ambassador for the City of London Corporation.

Rikin was an inaugural member of our Associate and Business Services Advisory Board which helps to facilitate regular, two-way communication and information flow between the Global Leadership Team and the associate and business services teams across the firm.

Mandate

Select Life Sciences experience

• Sanofi on the separation and exclusive negotiations with CD&R to transfer a 50% controlling stake in Opella, its consumer healthcare business.
• Novartis AG on the separation and spin-off of Sandoz, its €2.7 billion acquisition of MorphoSys AG and on various other M&A transactions.
• Grunenthal on its joint venture collaboration with Kyowa Kirin International.
• Cancer Research UK on the sale of the British Journal of Cancer to Springer Nature.
• Merck KGaA on the $4.2bn auction sale of its consumer healthcare business to Procter & Gamble.
• Boehringer Ingelheim on its €20bn asset swap with Sanofi and on various bolt-on acquisitions and anti-trust related divestments.

Select other experience

• Holcim on the sale of its business in Brazil to Companhia Siderúrgica Nacional for $1.025bn.
• National Bank of Greece on the sale of 90.01% of Ethniki Insurance to CVC Capital Partners' Fund VII.
• Softbank Group Corp. on its £24bn bid for ARM Holdings.
• Honeywell International Inc. on its $5.1bn acquisition of Melrose plc's utility metering business.
• UK Government on the sale of its interests in Eurostar and shareholdings in Lloyds and RBS.
• Guardian Media Group on various matters in relation to its Top Right Group and Auto Trader joint ventures.
• Rolls-Royce plc on various joint ventures.